The Effects of Dexamethasone and Ibuprofen on Postoperative Analgesia in Patients Undergoing Hand and Forearm Surgery With Axillary Brachial Plexus Block

May 20, 2026 updated by: Ayşegül Bilen, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
This study aims to comparatively examine the effects of preemptive intravenous dexamethasone and intravenous ibuprofen use on the duration of analgesia in ultrasound-guided Axillary Brachial Plexus Block applications for patients undergoing hand and forearm surgery. Furthermore, investigating the relationship between the study drugs and the incidence of Postoperative Nausea and Vomiting and determining the time until the first use of rescue analgesic are also among the secondary objectives.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

79

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34384
        • Prof. Dr. Cemil Tascioglu City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients aged between 18 and 65 years, with ASA physical status I or II, who were scheduled for hand or forearm surgery, were included in the study.

Description

Inclusion Criteria:

  • Patient's consent to participate in the study (Informed consent)
  • Aged between 18 and 65 years
  • ASA physical status I or II
  • Being oriented and cooperative
  • Scheduled to undergo hand or forearm surgery
  • Body Mass Index (BMI) below 40 kg/m²
  • Scheduled for axillary brachial plexus blockade

Exclusion Criteria:

  • Patient's refusal to participate in the study
  • Refusal of regional anesthesia
  • Known allergy to local anesthetics
  • Known allergy to ibuprofen
  • Known allergy to dexamethasone
  • Presence of coagulopathy
  • Local infection at the site of regional anesthesia application
  • Presence of malignancy at the surgical site
  • Diagnosis of diabetes mellitus
  • Body Mass Index (BMI) of 40 kg/m² or above
  • Duration of surgery exceeding 4 hours
  • Administration of opioid medication during the preoperative or intraoperative period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
D
Patients who had intravenouse dexamethasone
Drug: IV Dexamethasone 8mg
Patients who are in group D had intravenouse 8 mg dexamethasone before axillary brachial plexus blockade.
I
Patients who had intravenouse ibuprofen
Drug: iv ibuprofen
Patients who are in group I had intravenouse 400 mg ibuprofen before axillary brachial plexus blockade.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of analgesia
Time Frame: 24 hours
Duration of analgesia was defined as the time from the performance of the block until the patient's first report of pain.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of PONV
Time Frame: 24 hours
The incidence of PONV during the first 24 hours following the block administration will be evaluated.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2025

Primary Completion (Actual)

October 31, 2025

Study Completion (Actual)

October 31, 2025

Study Registration Dates

First Submitted

April 9, 2026

First Submitted That Met QC Criteria

April 9, 2026

First Posted (Actual)

April 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SBU-ANES-BCC-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dexamethasone

Clinical Trials on IV Dexamethasone 8mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe